PMID- 25146517
OWN - NLM
STAT- MEDLINE
DCOM- 20150520
LR  - 20181202
IS  - 0578-1426 (Print)
IS  - 0578-1426 (Linking)
VI  - 53
IP  - 6
DP  - 2014 Jun
TI  - [The outcome of thirteen patients with nonmalignant hematologic diseases treated 
      with HLA haploidentical stem cell transplantation].
PG  - 473-6
AB  - OBJECTIVE: To evaluate the clinical efficacy and safety of human leukocyte 
      antigen (HLA) haploidentical stem cell transplantation in nonmalignant 
      hematologic diseases. METHOD: To analyze the outcome of 13 patients with 
      nonmalignant hematologic diseases who underwent HLA haploidentical stem cell 
      transplantation from September 2001 to October 2013. RESULTS: Thirteen patients 
      including 9 of severe aplastic anemia, 3 of severe beta thalassemia, 1 of congenital 
      pure red cell aplastic anemia underwent HLA haploidentical stem cell 
      transplantation. Three HLA loci mismatched in 4 cases, two HLA loci mismatched in 
      8 cases and one HLA locus mismatched in 1 case. The conditioning regime consisted 
      of Fludarabine (30 mgxm(-2)xd(-1)x5 d ), Busulfan(0.8 mgxkg(-1)x6h(-1)x4 d), 
      Cyclophosphamide (60 mgxkg(-1)xd(-1)x2 d ), rabbit anti-human lymphocyte globulin 
      ( 2.5 mgxkg(-1)xd(-1)x5 d ). To prevent from graft-versus-host disease (GVHD), 
      cyclosporin A and short term methotrexate (MTX) were used. All patients were 
      successfully engrafted. The incidence of grade 1-2 acute graft-versus-host 
      disease (aGVHD) was 3/13, and that of grade 3-4 was 1/13. The cumulative 
      incidence of total chronic GVHD (cGVHD) was 3/13. Eleven patients survived free 
      of disease at a median follow-up period of 13 months (2-145). CONCLUSION: HLA 
      haploidentical stem cell transplantation is an effective and safe therapy for 
      nonmalignant hematologic diseases.
FAU - Tao, Yuan
AU  - Tao Y
AD  - Department of Hematology, Zhujiang Hospital, Southern Medical University, 
      Guangzhou 510280, China.
FAU - Wu, Bingyi
AU  - Wu B
AD  - Department of Hematology, Zhujiang Hospital, Southern Medical University, 
      Guangzhou 510280, China. Email: wubingyi@aliyun.com.
FAU - Du, Qingfeng
AU  - Du Q
AD  - Department of Hematology, Zhujiang Hospital, Southern Medical University, 
      Guangzhou 510280, China.
FAU - Sun, Can
AU  - Sun C
AD  - Department of Hematology, Zhujiang Hospital, Southern Medical University, 
      Guangzhou 510280, China.
FAU - Lin, Xia
AU  - Lin X
AD  - Department of Hematology, Zhujiang Hospital, Southern Medical University, 
      Guangzhou 510280, China.
FAU - Huang, Yuxian
AU  - Huang Y
AD  - Department of Hematology, Zhujiang Hospital, Southern Medical University, 
      Guangzhou 510280, China.
FAU - Tu, Sanfang
AU  - Tu S
AD  - Department of Hematology, Zhujiang Hospital, Southern Medical University, 
      Guangzhou 510280, China.
FAU - Song, Chaoyang
AU  - Song C
AD  - Department of Hematology, Zhujiang Hospital, Southern Medical University, 
      Guangzhou 510280, China.
FAU - Lu, Zhigang
AU  - Lu Z
AD  - Department of Hematology, Zhujiang Hospital, Southern Medical University, 
      Guangzhou 510280, China.
FAU - Chen, Tuzhen
AU  - Chen T
AD  - Department of Hematology, Zhujiang Hospital, Southern Medical University, 
      Guangzhou 510280, China.
FAU - Sun, Caixia
AU  - Sun C
AD  - Department of Hematology, Zhujiang Hospital, Southern Medical University, 
      Guangzhou 510280, China.
LA  - chi
PT  - Journal Article
PL  - China
TA  - Zhonghua Nei Ke Za Zhi
JT  - Zhonghua nei ke za zhi
JID - 16210490R
RN  - 0 (HLA Antigens)
RN  - FA2DM6879K (Vidarabine)
RN  - G1LN9045DK (Busulfan)
RN  - P2K93U8740 (fludarabine)
RN  - YL5FZ2Y5U1 (Methotrexate)
SB  - IM
MH  - Anemia, Aplastic
MH  - Busulfan
MH  - Graft vs Host Disease
MH  - HLA Antigens
MH  - Hematologic Diseases/*therapy
MH  - Histocompatibility
MH  - Humans
MH  - Incidence
MH  - Methotrexate
MH  - *Stem Cell Transplantation
MH  - Transplantation, Homologous
MH  - Treatment Outcome
MH  - Vidarabine/analogs & derivatives
EDAT- 2014/08/26 06:00
MHDA- 2015/05/21 06:00
CRDT- 2014/08/23 06:00
PHST- 2014/08/23 06:00 [entrez]
PHST- 2014/08/26 06:00 [pubmed]
PHST- 2015/05/21 06:00 [medline]
PST - ppublish
SO  - Zhonghua Nei Ke Za Zhi. 2014 Jun;53(6):473-6.